Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus NEO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus NEO RX.
CHLOROMYXIN vs NEO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
100 mg intravenously every 12 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 2.5-3 hours in adults with normal renal function; increased to up to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinically, this supports 8-hourly dosing intervals in normal renal function, with extended intervals in renal impairment.
CHLOROMYXIN is not a recognized drug. No data available.
Renal excretion accounts for 90-100% of elimination, primarily as the parent drug via glomerular filtration and tubular secretion. Urinary excretion: 90-100% unchanged. Fecal/biliary: negligible (<2%).
Category C
Category C
Antibiotic
Antibiotic